4-MeO-MiPT Stats & Data

Psychedelic Research-chemical

Chemical Class Phenethylamine

Psychoactive Class Psychedelic

Half-Life Not formally studied in humans; user reports suggest primary effects typically resolve within ~6 h after oral dosing.

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (partial)

5-HT1A receptor agonist

Inhibitors

Serotonin reuptake inhibitor (selective, SSRI)

Effect Profile

Curated + 7 Reports

Psychedelic 3.8

Strong auditory effects with moderate body load, mild visuals, low headspace

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Based on reports from:

Effect Index Vestiges of a Trip — nervewing TiHKAL TiHKAL #39: 4-MeO-MIPT Erowid Experience Reports PsychonautWiki 4-MeO-MiPT

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Not formally studied in humans; user reports suggest primary effects typically resolve within ~6 h after oral dosing.

Addiction Potential

Very low. Like other serotonergic psychedelics it is not associated with compulsive use or physical dependence; rapid tolerance discourages frequent redosing.

Tolerance Decay

Full tolerance 1d Half tolerance 3d Baseline ~10d

Rapid tolerance like other 5‑HT2A psychedelics; spacing sessions by 10–14 days helps restore baseline sensitivity. Evidence level: anecdotal/user‑report across tryptamines; no pharmacokinetic studies for 4‑MeO‑MiPT.

Cross-Tolerances

Other serotonergic psychedelics (e.g., LSD, psilocybin, 4‑HO/4‑AcO tryptamines)

60% ●○○

Experience Report Analysis

Erowid

7 Reports

2007–2019 Date Range

6 With Age Data

14 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 7 experience reports (7 Erowid)

7 Reports

14 Effects Detected

7 Positive

2 Adverse

5 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 7

Empathy 85.7% 70%

Color Enhancement 85.7% 70%

Music Enhancement 71.4% 70%

Euphoria 57.1% 70%

Focus Enhancement 57.1% 70%

Stimulation 42.9% 70%

Body High 42.9% 70%

Adverse Effects 2

Anxiety 42.9% 70%

Muscle Tension 42.9% 70%

Real-World Dose Distribution

62K Doses

From 15 individual dose entries

Oral (n=14)

Median: 19.0mg 25th: 9.25mg 75th: 25.0mg 90th: 38.5mg

mg/kg median: 0.228 mg/kg 75th: 0.34

Form / Preparation

Most common forms and preparations reported

Read full reports on Erowid →

Harm Reduction

drugs.wiki

Harm-reduction clarifications and updates:

• Avoid nickname confusion: “Moxy” commonly refers to 5‑MeO‑MiPT, not 4‑MeO‑MiPT; mislabeling has led to hazardous outcomes in the past. Verify substance identity before dosing.

• Allergy test every new batch: With rare RCs, start with ~1 mg oral allergy test at least 24 h before any active dose; this is a longstanding HR practice echoed by Erowid.

• Reagent testing helps only as a first-pass screen: Indole tryptamines react positive with Ehrlich; many tryptamines (incl. 5‑MeO‑MiPT) give yellow→black with Marquis. Reagents cannot confirm 4‑MeO‑MiPT identity; send to a lab if possible.

• Measurement matters: Use a 0.001 g scale or volumetric dosing for precise titration of small doses. Avoid eyeballing powders. TripSit provides a volumetric converter tool.

• Duration tends to be short/moderate with a tactile, sociable headspace; several users find 20–30 mg oral to produce mild-to-moderate effects with limited visuals. Stronger effects are possible near the top of the range; titrate cautiously.

• Combining 4‑oxygenated tryptamines with 5‑MeO tryptamines can yield unexpectedly strong effects; if combining at all, lower both doses and have a sitter.

• Polydrug risks: The general combo literature flags MAOIs, tramadol, DXM, and serotonergic antidepressants as higher‑risk pairings due to serotonin toxicity or seizure risk; treat these as contraindicated unless medically supervised.

• Because samples are rare and data sparse, expect variability across batches and treat all data as provisional; prefer single‑substance trials and avoid stacking on first exposures.